Get started
Gain Therapeutics, Inc.Gain Therapeutics, Inc.Gain Therapeutics, Inc.

Gain Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

GANX chart


Full chart

GANX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪42.97 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.11 USD
Net income (FY)
‪−22.27 M‬ USD
Revenue (FY)
‪55.18 K‬ USD
Shares float
‪25.17 M‬
Beta (1Y)
2.02

Employees


Employees (FY)
32
Change (1Y)
0
Revenue / Employee (1Y)
‪1.72 K‬ USD
Net income / Employee (1Y)
‪−695.86 K‬ USD

About Gain Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Gene C. Mack
Website
gaintherapeutics.com
Headquarters
Bethesda
Founded
2017
FIGI
BBG00W7D7CJ9
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

GANX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of GANX is 1.72 USD — it has decreased by −2.41% in the past 24 hours. Watch Gain Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Gain Therapeutics, Inc. stocks are traded under the ticker GANX.
GANX stock has fallen by −20.20% compared to the previous week, the month change is a −42.14% fall, over the last year Gain Therapeutics, Inc. has showed a −22.17% decrease.
We've gathered analysts' opinions on Gain Therapeutics, Inc. future price: according to them, GANX price has a max estimate of 10.00 USD and a min estimate of 5.00 USD. Watch GANX chart and read a more detailed Gain Therapeutics, Inc. stock forecast: see what analysts think of Gain Therapeutics, Inc. and suggest that you do with its stocks.
GANX reached its all-time high on Apr 12, 2021 with the price of 17.93 USD, and its all-time low was 0.89 USD and was reached on Aug 13, 2024. View more price dynamics on GANX chart.
See other stocks reaching their highest and lowest prices.
GANX stock is 14.04% volatile and has beta coefficient of 2.02. Track Gain Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Gain Therapeutics, Inc. there?
Today Gain Therapeutics, Inc. has the market capitalization of ‪42.97 M‬, it has decreased by −12.20% over the last week.
Yes, you can track Gain Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Gain Therapeutics, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
GANX earnings for the last quarter are −0.17 USD per share, whereas the estimation was −0.21 USD resulting in a 17.96% surprise. The estimated earnings for the next quarter are −0.19 USD per share. See more details about Gain Therapeutics, Inc. earnings.
Gain Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪10.00 K‬ USD. In the next quarter, revenue is expected to reach ‪23.33 K‬ USD.
GANX net income for the last quarter is ‪−4.49 M‬ USD, while the quarter before that showed ‪−8.14 M‬ USD of net income which accounts for 44.91% change. Track more Gain Therapeutics, Inc. financial stats to get the full picture.
No, GANX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 32.00 employees. See our rating of the largest employees — is Gain Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Gain Therapeutics, Inc. EBITDA is ‪−21.34 M‬ USD, and current EBITDA margin is ‪−40.18 K‬%. See more stats in Gain Therapeutics, Inc. financial statements.
Like other stocks, GANX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Gain Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Gain Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Gain Therapeutics, Inc. stock shows the sell signal. See more of Gain Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.